ReviewNature reviews. Neurology2020
Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.
Review in Nature reviews. Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Multiple sclerosis and inflammatory bowel disease: A systematic review and meta-analysis.Annals of clinical and translational neurology · 2022Pooled it
- Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Trial
- French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4.Journal of neurology · 2026Review
- Article
- Building Towards Initiation, Moderation, De-Escalation and Cessation of Disease-Modifying Treatments for Multiple Sclerosis in Greece: An Expert Panel Consensus Meeting.Brain sciences · 2026Article
- Extensive peripheral immunoglobulin repertoire analyses in people with multiple sclerosis reveal disease-specific signatures and distinct treatment effects of disease modifying drugs.Journal of neuroinflammation · 2026Article
- CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy.Journal of neuroinflammation · 2026Review
- CAR T-Cell Immunotherapy in Neuroautoimmune Diseases: Focus on the Central Nervous System.Biomedicines · 2026Review
- Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.Therapeutic advances in neurological disorders · 2026Review
- Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Experimental hematology & oncology · 2025Review
- De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.Brain : a journal of neurology · 2025Review
- Deciphering Autoimmune Diseases: Unveiling the Diagnostic, Therapeutic, and Prognostic Potential of Immune Repertoire Sequencing.Inflammation · 2025Review
- Cladribine tablets in the new multiple sclerosis era.Therapeutic advances in neurological disorders · 2025Review
- Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry.Therapeutic advances in neurological disorders · 2025Article
- New autoimmune disorder development after immune reconstitution therapy for multiple sclerosis.Scientific reports · 2024Article
- Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Overview of emerging therapies for demyelinating diseases.World journal of clinical cases · 2024Review
- Real-world persistence of multiple sclerosis disease-modifying therapies.European journal of neurology · 2024Article
- Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.Annals of clinical and translational neurology · 2024Observational
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
New so-called immune reconstitution therapies (IRTs) have the potential to induce long-term or even permanent drug-free remission in people with multiple sclerosis (MS). These therapies deplete components of the immune system with the aim of allowing the immune system to renew itself. Haematopoietic stem cell transplantation, the oral formulation cladribine and the monoclonal antibodies alemtuzumab, rituximab and ocrelizumab are frequently categorized as IRTs. However, the evidence that IRTs indeed renew adaptive immune cell repertoires and rebuild a healthy immune system in people with MS is variable. Instead, IRTs might foster the expansion of those cells that survive immunosuppression, and this expansion could be associated with acquisition of new functional phenotypes. Understanding immunological changes induced by IRTs and how they correlate with clinical outcomes will be instrumental in guiding the optimal use of immune reconstitution as a durable therapeutic strategy. This Perspectives article critically discusses the efficacy and potential mechanisms of IRTs in the context of immune system renewal and durable disease remission in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.